publication date: Mar. 8, 2019
NCI Trials NCI Trials for March
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10214
Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Lipson, Evan Jacob
(410) 502-5977
Phase I – 10241
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
NCI Center for Cancer Research
Miljkovic, Miloa
(301) 250-5216
Phase I – 10246
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
University Health Network Princess Margaret Cancer Center LAO
Shafer, Danielle A
(804) 628-0279
Phase I/II – 10195
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
Duke University – Duke Cancer Institute LAO
Dees, Elizabeth Claire
(919) 843-7714
Continue reading NCI Trials for March 2019
To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
